These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Association of tardive dyskinesia with variation in CYP2D6: Is there a role for active metabolites? Koola MM; Tsapakis EM; Wright P; Smith S; Kerwin Rip RW; Nugent KL; Aitchison KJ J Psychopharmacol; 2014 Jul; 28(7):665-70. PubMed ID: 24595968 [TBL] [Abstract][Full Text] [Related]
3. Cytochrome P-450 2D6*10 C188T polymorphism is associated with antipsychotic-induced persistent tardive dyskinesia in Chinese schizophrenic patients. Liou YJ; Wang YC; Bai YM; Lin CC; Yu SC; Liao DL; Lin MW; Chen JY; Lai IC Neuropsychobiology; 2004; 49(4):167-73. PubMed ID: 15118351 [TBL] [Abstract][Full Text] [Related]
4. Genetic polymorphisms for drug metabolism (CYP2D6) and tardive dyskinesia in schizophrenia. Kapitany T; Meszaros K; Lenzinger E; Schindler SD; Barnas C; Fuchs K; Sieghart W; Aschauer HN; Kasper S Schizophr Res; 1998 Jul; 32(2):101-6. PubMed ID: 9713905 [TBL] [Abstract][Full Text] [Related]
5. Pharmacogenetics of tardive dyskinesia: an updated review of the literature. Lanning RK; Zai CC; Müller DJ Pharmacogenomics; 2016 Aug; 17(12):1339-51. PubMed ID: 27469238 [TBL] [Abstract][Full Text] [Related]
6. Tardive dyskinesia and debrisoquine 4-hydroxylase (CYP2D6) genotype in Japanese schizophrenics. Ohmori O; Suzuki T; Kojima H; Shinkai T; Terao T; Mita T; Abe K Schizophr Res; 1998 Jul; 32(2):107-13. PubMed ID: 9713906 [TBL] [Abstract][Full Text] [Related]
7. Association study between the neurexin-1 gene and tardive dyskinesia. Lanning R; Lett TA; Tiwari AK; Brandl EJ; de Luca V; Voineskos AN; Potkin SG; Lieberman JA; Meltzer HY; Müller DJ; Remington G; Kennedy JL; Zai CC Hum Psychopharmacol; 2017 Jan; 32(1):. PubMed ID: 28120489 [TBL] [Abstract][Full Text] [Related]
8. Association of CYP2D6 and CYP1A2 gene polymorphism with tardive dyskinesia in Chinese schizophrenic patients. Fu Y; Fan CH; Deng HH; Hu SH; Lv DP; Li LH; Wang JJ; Lu XQ Acta Pharmacol Sin; 2006 Mar; 27(3):328-32. PubMed ID: 16490169 [TBL] [Abstract][Full Text] [Related]
9. Schizophrenia-associated gene dysbindin-1 and tardive dyskinesia. Maes MS; Lu JY; Tiwari AK; Freeman N; de Luca V; Müller DJ; Voineskos AN; Potkin SG; Lieberman JA; Meltzer HY; Remington G; Kennedy JL; Zai CC Drug Dev Res; 2021 Aug; 82(5):678-684. PubMed ID: 32394511 [TBL] [Abstract][Full Text] [Related]
10. Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: III. Lack of association of CYP3A4 and CYP2D6 gene polymorphisms. Tiwari AK; Deshpande SN; Rao AR; Bhatia T; Lerer B; Nimgaonkar VL; Thelma BK Schizophr Res; 2005 Jun; 75(1):21-6. PubMed ID: 15820320 [TBL] [Abstract][Full Text] [Related]
11. CYP2D6 polymorphisms and the risk of tardive dyskinesia in schizophrenia: a meta-analysis. Patsopoulos NA; Ntzani EE; Zintzaras E; Ioannidis JP Pharmacogenet Genomics; 2005 Mar; 15(3):151-8. PubMed ID: 15861039 [TBL] [Abstract][Full Text] [Related]
12. CYP2D6 polymorphism and tardive dyskinesia in schizophrenic patients. Lohmann PL; Bagli M; Krauss H; Müller DJ; Schulze TG; Fangerau H; Ludwig M; Barkow K; Held T; Heun R; Maier W; Rietschel M; Rao ML Pharmacopsychiatry; 2003; 36(2):73-8. PubMed ID: 12734765 [TBL] [Abstract][Full Text] [Related]
13. Abnormal movements and tardive dyskinesia in smokers and nonsmokers with schizophrenia genotyped for cytochrome P450 2D6. Ellingrod VL; Schultz SK; Arndt S Pharmacotherapy; 2002 Nov; 22(11):1416-9. PubMed ID: 12432967 [TBL] [Abstract][Full Text] [Related]
14. CYP1A2 and CYP2D6 Gene Polymorphisms in Schizophrenic Patients with Neuroleptic Drug-Induced Side Effects. Ivanova SA; Filipenko ML; Vyalova NM; Voronina EN; Pozhidaev IV; Osmanova DZ; Ivanov MV; Fedorenko OY; Semke AV; Bokhan NA Bull Exp Biol Med; 2016 Mar; 160(5):687-90. PubMed ID: 27021090 [TBL] [Abstract][Full Text] [Related]
15. CYP2D6 genotype predicts antipsychotic side effects in schizophrenia inpatients: a retrospective matched case-control study. Kobylecki CJ; Jakobsen KD; Hansen T; Jakobsen IV; Rasmussen HB; Werge T Neuropsychobiology; 2009; 59(4):222-6. PubMed ID: 19521114 [TBL] [Abstract][Full Text] [Related]
16. Analysis of schizophrenia-associated genetic markers in the HLA region as risk factors for tardive dyskinesia. Wang R; Lu JY; Herbert D; Lieberman JA; Meltzer HY; Tiwari AK; Remington G; Kennedy JL; Zai CC Hum Psychopharmacol; 2024 Jul; 39(4):e2898. PubMed ID: 38676936 [TBL] [Abstract][Full Text] [Related]
17. Non-functional CYP2D6 alleles and risk for neuroleptic-induced movement disorders in schizophrenic patients. Andreassen OA; MacEwan T; Gulbrandsen AK; McCreadie RG; Steen VM Psychopharmacology (Berl); 1997 May; 131(2):174-9. PubMed ID: 9201806 [TBL] [Abstract][Full Text] [Related]
18. Tardive dyskinesia: Who gets it and why. Frei K Parkinsonism Relat Disord; 2019 Feb; 59():151-154. PubMed ID: 30522959 [TBL] [Abstract][Full Text] [Related]
19. Genetic study of neuregulin 1 and receptor tyrosine-protein kinase erbB-4 in tardive dyskinesia. Zai CC; Tiwari AK; Chowdhury NI; Yilmaz Z; de Luca V; Müller DJ; Potkin SG; Lieberman JA; Meltzer HY; Voineskos AN; Remington G; Kennedy JL World J Biol Psychiatry; 2019 Jan; 20(1):91-95. PubMed ID: 28394697 [TBL] [Abstract][Full Text] [Related]
20. Association study of Disrupted-In-Schizophrenia-1 gene variants and tardive dyskinesia. Lu JY; Tiwari AK; Zai GC; Rastogi A; Shaikh SA; Müller DJ; Voineskos AN; Potkin SG; Lieberman JA; Meltzer HY; Remington G; Wong AHC; Kennedy JL; Zai CC Neurosci Lett; 2018 Nov; 686():17-22. PubMed ID: 30118782 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]